Manufacturing and quality control of plasmid-based gene expression systems

Advanced Drug Delivery Reviews

Volumn 30, Issue 1-3, 1998, Pages 33-48

  Durland, Ross H ^a   Eastman, Eric M ^b  

^a GeneMedicine Inc   (United States)

^b Gene Logic Inc   (United States)

Author keywords

DNA; DNA purification; Fermentation; Gene expression; Gene therapy; Manufacturing; Nucleic acid vaccines; Plasmid; Quality control

Indexed keywords

DISEASES; DNA; DRUG THERAPY; FERMENTATION; GENES; GENETIC ENGINEERING; MANUFACTURE; PATIENT TREATMENT; PROTEINS; PURIFICATION; QUALITY CONTROL;

DNA PURIFICATION; GENE EXPRESSION; GENE THERAPY; NUCLEIC ACID VACCINES; PLASMID;

DRUG PRODUCTS;

PLASMID VECTOR;

ANIMAL CELL; DNA PURIFICATION; DRUG DESIGN; DRUG MANUFACTURE; FERMENTATION; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; QUALITY CONTROL; RECOMBINANT GENE; REVIEW; TECHNIQUE; VACCINE PRODUCTION;

EID: 0032473583     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00105-1     Document Type: Review

References (61)

1. Haynes J.R., Fuller D.H., McCabe D., Swain W.F., Widers G. Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Adv. Drug Del. Rev. 21:1996;3-18.
2. Shiver J.W., Ulmer J.B., Donnelly J.J., Liu M.A. Humoral and cellular immunities elicited by nucleic acid vaccines: application to the human immunodeficiency virus and influenza. Adv. Drug Del. Rev. 21:1996;19-31.
3. Davis H.L. DNA-based vaccination against Hepatitis B virus. Adv. Drug Del. Rev. 21:1996;33-47.
4. Doolan D.L., Sedagah M., Hedstrom R.C., Aquiar J.C., Hoffman S.L. DNA vaccination against Malaria. Adv. Drug Del. Rev. 21:1996;49-61.
5. Babiuk L.A., Rouse B.T. Herpesvirus vaccines. Adv. Drug Del. Rev. 21:1996;63-76.
6. Anderson W.F. Gene therapy. Sci. Am. 273:1995;124-128.
7. Ledley F.D. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum. Gene Ther. 6:1995;1129-1144.
8. Ledley F.D. Non-viral gene therapies. Curr. Opin. Biotechnol. 5:1994;626-636.
9. K.W. Culver, Gene Therapy: A Handbook for Physicians, Mary Ann Leibert, New York, 1994, pp. 15-31.
10. Smith K.T., Shepard A.J., Boyd J.E., Lees G.M. Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Gene Ther. 3:1996;190-200.
11. A. Rolland, E. Tomlinson, Controllable gene therapy using nonviral systems, in: P.L. Felgner, M.J. Heller, P. Lehn, J.P. Behr, F.C. Szoka, Jr. (Eds.), Artificial Self-Assembling Systems for Gene Delivery, American Chemical Society, Washington D.C., 1996, pp. 86-100.
12. Marquet M., Horn N.A., Meek J.A. Process development for the manufacture of plasmid DNA vectors for use in gene therapy. Biopharm. 8:1995;26-37.
13. DoHHS, Interim definition and elimination of lot-by-lot release for well-characterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology products. Notice Fed. Reg. 60, 1995, 63048-63059.
14. DoHHS, Elimination of establishment license application for specified biotechnology and specified synthetic biological products. Notice Fed. Reg. 61, 1996, 24227-24233.
15. Wechsler J. Doing more with less at FDA. Biopharm. 9(10):1996;18-22.
16. Little L.E. Keeping on track: current quality control trends. Biopharm. 9(5):1996;72-77.
17. Bolivar F., Rodriguez R.L., Greene P.J., Betlach M.C., Heyneker H.L., Boyer H.W., Crosa J.H., Falkow S. Construction and characterization of new cloning vehicles II. A multipurpose cloning system. Gene. 2:1977;95-113.
18. Vieira J., Messing J. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. Gene. 19:1982;259-268.
19. Balbas P., Soberon X., Merino E., Zurita M., Lomeli H., Valle F., Flores N., Bolivar F. Plasmid vector pBR322 and its special-purpose derivatives - a review. Gene. 50:1986;3-40.
20. Davison J. Mechanism of control of DNA replication and incompatibility in ColE1-type plasmids - a review. Gene. 28:1984;1-15.
21. Imanaka T., Aiba S. A perspective on the application of genetic engineering: stability of recombinant plasmid. Ann. N.Y. Acad. Sci. 369:1981;1-14.
22. Seo J.-H., Bailey J.E. Effects of recombinant plasmid content on growth properties and cloned gene product formation in Escherichia coli. Biotech. Bioeng. 27:1985;1668-1674.
23. DoHHS, Addendum to the points to consider in human somatic cell and gene therapy, 1991 (Draft), January, 1996.
24. Skogman S.G., Nilsson J. Temperature-dependent retention of a tryptophan-operon-bearing plasmid in Escherichia coli. Gene. 31:1984;117-122.
25. Porter R.D., Black S., Pannuri S., Carlson A. Use of the Escherichia coli ssb gene to prevent bioreactor takeover by plasmidless cells. Bio/Technol. 8:1990;47-51.
26. DoHHS, Points to consider in the characterization of cell lines used to produce biologicals, 1993.
27. Dorman C.J., Barr G.C., Bhriain N.N., Higgins C.F. DNA supercoiling and the anaerobic and growth phase regulation of tonB gene expression. J. Bacteriol. 170:1988;2816-2826.
28. Goldstein E., Drlica K. Regulation of bacterial DNA supercoiling: plasmid linking numbers vary with growth temperature. Proc. Natl. Acad. Sci. USA. 81:1984;4046-4050.
29. Horn N.A., Meek J.A., Budahazi G., Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum. Gene Ther. 6:1995;565-573.
30. N.C. Wan, J.C. Goodrick, Method for increasing plasmid yield. United States Patent #5, 1996, 487,986.
31. Lahijani R., Hulley G., Soriano G., Horn N.A., Marquet M. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum. Gene Ther. 7:1996;1971-1980.
32. Birnboim H.C., Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7:1979;1513-1523.
33. Wicks I.P., Howell M.L., Hancock T., Kohsaka H., Olee T., Carson D.A. Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy. Hum. Gene Ther. 6:1995;317-323.
34. Davis H.L., Schleef M., Moritz P., Mancini M., Schorr J., Whalen R.G. Comparison of plasmid DNA preparation methods for direct gene transfer and genetic immunization. Biotechniques. 21:1996;92-99.
35. Thompson J.A. A review of high-performance liquid chromatography in nucleic acids research. III. Isolation, purification, and analysis of supercoiled plasmid DNA. Biochrom. 1:1986;68-80.
36. Chandra G., Patel P., Kost T.A., Gray J.G. Large-scale purification of plasmid DNA by fast protein liquid chromatography using a Hi-Load Q Sepharose column. Anal. Biochem. 203:1992;169-172.
37. Hines R.H., O'Connor K.C., Vella G., Warren W. Large- scale purification of plasmid DNA by anion-exchange high-performance liquid chromatography. Biotechniques. 12:1992;430-434.
38. Kasai K. Size-dependent chromatographic separation of nucleic acids. J. Chrom. 618:1993;203-221.
39. Vo-Quang T., Malpiece Y., Buffard D., Kaminski P.A., Vidal D., Strosberg A.D. Rapid large-scale purification of plasmid DNA by medium or low pressure gel filtration. Application: construction of thermoamplifiable expression vectors. Biosci. Rep. 5:1985;101-111.
40. Best A.N., Allison D.P., Novelli G.D. Purification of supercoiled DNA of plasmid Col E1 by RPC-5 chromatography. Anal. Biochem. 114:1981;235-243.
41. 18 silica beads. Anal. Biochem. 135:1983;345-348.
42. Kapp U., Langowski J. Preparation of DNA topoisomers by RP-18 high-performance liquid chromatography. Anal. Biochem. 206:1992;293-299.
43. Colman A., Byers M.J., Primrose S.B., Lyons A. Rapid purification of plasmid DNAs by hydroxyapatite chromatography. Eur. J. Biochem. 91:1978;303-310.
44. Ohlsson R., Hentschel C.C., Williams J.G. A rapid method for the isolation of circular DNA using an aqueous two-phase partition system. Nucleic Acids Res. 5:1978;583-590.
45. Gossen J.A., de Leeuw W.J.F., Molijn A.C., Vijg J. Plasmid rescue from transgenic mouse DNA using LacI repressor protein conjugated to magnetic beads. Biotechniques. 14:1993;624-629.
46. Ito T., Smith C.L., Cantor C.R. Sequence-specific DNA purification by triplex affinity capture. Proc. Natl. Acad. Sci. USA. 89:1992;495-498.
47. Ji H., Smith L.M. Rapid purification of double-stranded DNA by triple-helix-mediated affinity capture. Anal. Chem. 65:1993;1323-1328.
48. Caplen N.J., Gao X., Hayes P., Elaswarapu R., Fisher G., Kinrade E., Chakera A., Schorr J., Hughes B., Dorin J.R., Porteous D.J., Alton E.W.F.W., Geddes D.M., Coutelle C., Williamson R., Huang L., Gilchrist C. Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. Gene Ther. 1:1994;139-147.
49. M. Marquet, N. Horn, J. Meek, G. Budahazi, Production of pharmaceutical-grade plasmid DNA. World Intellectual Propery Organization pub. 1995, #WO 95/21250.
50. M. Marquet, N. Horn, J. Meek, G. Budahazi, Production of pharmaceutical-grade plasmid DNA. United States Patent, 1996, #5, 561,064.
51. A.L. Lee, S. Sagar, A method for large scale plasmid purification. World Intellectual Propery Organization pub. 1996, #WO 96/02658.
52. Steuer A., Ostrove J.M. Establishing cell banks under current good manufacturing practices. Biopharm. 9(6):1996;40-44.
53. DoHHS, Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability. April 6, 1992.
54. Smith H.A. Regulatory considerations for nucleic acid vaccines. Vaccine. 12:1994;1515-1519.
55. DoHHS, Points to consider on plasmid nucleic acid vaccines for preventive infectious disease indications (Draft), October, 1996.
56. Del Tito B.J. Jr., Trembley M.A., Shadle P.J. Qualification of raw materials for clinical biopharmaceutical manufacturing. Biopharm. 9(10):1996;45-49.
57. Manthorpe M., Cornefert-Jensen F., Hartikka J., Felgner J., Rundell A., Margalith M., Dwarki V. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum. Gene Ther. 4:1993;419-431.
58. Weintraub H., Cheng P.F., Conrad K. Expression of transfected DNA depends on DNA topology. Cell. 46:1986;115-122.
59. Piña B., Haché R.J.G., Arnemann J., Chalepakis G., Slater E.P., Beato M. Hormonal induction of transfected genes depends on DNA topology. Mol. Cell. Biol. 10:1990;625-633.
60. Bevilacqua A., Mangia F. Activity of a microinjected inducible murine hsp68 gene promoter depends on plasmid configuration and the presence of heat shock elements in mouse dictyate oocytes but not in two-cell embryos. Devel. Genet. 14:1993;92-102.
61. Buttrick P.M., Kass A., Kitsis R.N., Kaplan M.L., Leinwand L.A. Behavior of genes directly injected into the rat heart in vivo. Circ. Res. 70:1992;193-198.